Amgen + BeOne Medicines (formerly BeiGene)
Amgen
Thousand Oaks, California · 1 relationship
Active relationship
Strategic Partnership · 2020–present
BeOne Medicines (formerly BeiGene)
Basel, Switzerland · 1 relationship
Analysis
Amgen and BeiGene made their global oncology collaboration effective on January 2, 2020. Amgen acquired approximately 20.5 percent of BeiGene for about $2.8 billion in cash, and a former Amgen executive joined BeiGene's board as the companies began the relationship. [1] [2]
BeiGene received responsibility for commercializing Amgen's XGEVA, KYPROLIS and BLINCYTO in mainland China during product-specific periods, with the parties sharing profits and losses equally. The original terms provided for some product rights to return to Amgen after five or seven years while BeiGene could retain one product and receive time-limited royalties on products returned. [1] [3]
The development side initially covered 20 medicines in Amgen's oncology pipeline. BeiGene agreed to contribute cash and development services worth up to $1.25 billion toward global research and development, while obtaining Chinese development and commercialization roles and sharing China profits for defined periods; Amgen could use data from China trials in global development. [1] [3]
BeiGene's 2024 annual filing continued to describe the Amgen agreement, including development and commercialization in China and joint global development of oncology assets. That continuing disclosure supports treating the relationship as active, while also showing that it is governed by product-level termination, reversion and royalty provisions rather than a permanent transfer of Amgen's portfolio. [4]
Participants
Continue through either entity
Thousand Oaks, California · 1 record in this database
Amgen was established in Thousand Oaks, California, on April 8, 1980, as AMGen, or Applied Molecular Genetics, with an initial staff of three. The company grew out of the early biotechnology field and set its scientific direction around using molecular biology to develop treatments for disease. [1]
Amgen's early research produced two defining medicines. In 1983, researchers cloned the human erythropoietin gene, enabling the development of EPOGEN; the U.S. Food and Drug Administration approved EPOGEN in 1989. A separate team cloned granulocyte colony-stimulating factor in 1985, leading to NEUPOGEN, which received FDA approval in 1991. Amgen and Kirin also formed the Kirin-Amgen joint venture in 1984 to commercialize erythropoietin worldwide. [1]
Today Amgen describes itself as a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. It reports a presence in approximately 100 countries and focuses on general medicine, rare disease, inflammation and oncology, with current research using biology, technology and human genetic data to pursue new medicines. [2] [3]
Amgen operates as one human-therapeutics segment and maintains major research centers in the United States, Iceland and the United Kingdom. In 2025 it opened a drug-substance facility in Holly Springs, North Carolina, broke ground on a second facility there, expanded manufacturing in Ohio and Puerto Rico, and began construction of a new science and innovation center at its Thousand Oaks headquarters. [3]
BeOne Medicines (formerly BeiGene)
Basel, Switzerland · 1 record in this database
BeOne Medicines Ltd., formerly BeiGene, is a global oncology company. The legal entity completed its continuation from the Cayman Islands to Switzerland and changed its English name to BeOne Medicines Ltd. on May 27, 2025; its 2025 Form 10-K lists principal executive offices in Basel, Switzerland. [1] [2]
The company's history identifies John V. Oyler and Xiaodong Wang as the founders who launched the business in 2010. An earlier SEC filing describes the organization as having started as a Beijing research-and-development company and then developing significant commercial, manufacturing and research capabilities in China and the United States. BeOne's current corporate history presents that origin as the beginning of a global oncology platform. [3] [4]
The company's 2025 Form 10-K lists BRUKINSA (zanubrutinib), a BTK inhibitor, as approved in 77 markets with global commercial rights, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody, as approved in 51 markets with global rights. It also lists PARTRUVIX (pamiparib), sonrotoclax and other commercial or registration-stage products, alongside an oncology pipeline spanning hematologic malignancies and solid tumors. [1]
BeOne reports operations across six continents, more than 45 countries and regions with clinical trials planned or enrolled, more than 190 clinical trials initiated, approximately 12,000 employees and regulatory approvals for three internally developed medicines in more than 80 countries. Its relevance to this database also includes a collaboration with Amgen: the 2019 agreement covered commercialization of XGEVA, KYPROLIS and BLINCYTO in China and development and future China commercialization of up to 20 Amgen pipeline products. [5] [4]